Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 27, 2015, Pages 8278-8283

  Huang, Sheng Xiong ^a   Yun, Bong Sik ^b   Ma, Ming ^a   Basu, Hirak S ^c   Church, Dawn R ^c   Ingenhorst, Gudrun ^b   Huang, Yong ^b   Yang, Dong ^a   Lohman, Jeremy R ^a   Tang, Gong Li ^b   Ju, Jianhua ^b   Liu, Tao ^b   Wilding, George ^c,d   Shen, Ben ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cancer targeting; Drug discovery; Natural product; Pathway engineering; Sulfur metabolism

Indexed keywords

ANTINEOPLASTIC AGENT; EPISULFONIUM ION; LEINAMYCIN E1; PRODRUG; REACTIVE OXYGEN METABOLITE; SULFONIUM DERIVATIVE; THIOL DERIVATIVE; UNCLASSIFIED DRUG; LACTAM; LEINAMYCIN; MACROLIDE; THIAZOLE DERIVATIVE; THIOKETONE;

ARTICLE; BIOSYNTHESIS; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA ALKYLATION; DRUG ISOLATION; DRUG STRUCTURE; FUNGAL STRAIN; HYDROXYLATION; IC50; LNCAP CELL LINE; MUTANT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; STREPTOMYCES; STREPTOMYCES ATROOLIVACUES; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

STREPTOMYCES ATROOLIVACEUS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTAMS; MACROLIDES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOLECULAR STRUCTURE; PRODRUGS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; STREPTOMYCES; THIAZOLES; THIONES;

EID: 84936112729     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1506761112     Document Type: Article

References (36)

1. Hara M, et al. (1989) Leinamycin, a new antitumor antibiotic from Streptomyces: Producing organism, fermentation and isolation. J Antibiot (Tokyo) 42(12):1768-1774.
2. Hara M, Saitoh Y, Nakano H (1990) DNA strand scission by the novel antitumor antibiotic leinamycin. Biochemistry 29(24):5676-5681.
3. Ashizawa T, et al. (1999) Antitumor activity of KF22678, a novel thioester derivative of leinamycin. Anticancer Drugs 10(9):829-836.
4. Gates KS (2000) Mechanisms of DNA damage by leinamycin. Chem Res Toxicol 13(10): 953-956.
5. Asai A, et al. (1996) Thiol-mediated DNA alkylation by the novel antitumor antibiotic leinamycin. J Am Chem Soc 118(28):6802-6803.
6. Breydo L, Zang H, Mitra K, Gates KS (2001) Thiol-independent DNA alkylation by leinamycin. J Am Chem Soc 123(9):2060-2061.
7. Nooner T, Dutta S, Gates KS (2004) Chemical properties of the leinamycin-guanine adduct in DNA. Chem Res Toxicol 17(7):942-949.
8. Viswesh V, Gates K, Sun D (2010) Characterization of DNA damage induced by a natural product antitumor antibiotic leinamycin in human cancer cells. Chem Res Toxicol 23(1):99-107.
9. Fekry MI, et al. (2011) Noncovalent DNA binding drives DNA alkylation by leinamycin: Evidence that the Z,E-5-(thiazol-4-yl)-penta-2,4-dienone moiety of the natural product serves as an atypical DNA intercalator. J Am Chem Soc 133(44):17641-17651.
10. Viswesh V, Hays AM, Gates K, Sun D (2012) DNA cleavage induced by antitumor antibiotic leinamycin and its biological consequences. Bioorg Med Chem 20(14):4413-4421.
11. Sivaramakrishnan S, Breydo L, Sun D, Gates KS (2012) The macrocycle of leinamycin imparts hydrolytic stability to the thiol-sensing 1,2-dithiolan-3-one 1-oxide unit of the natural product. Bioorg Med Chem Lett 22(11):3791-3794.
12. Mitra K, Kim W, Daniels JS, Gates KS (1997) Oxidative DNA cleavage by the antitumor antibiotic leinamycin and simple 1,2-dithiolan-3-one 1-oxides: Evidence for thiodependent conversion of molecular oxygen to DNA-cleaving oxygen radicals mediated by polysulfides. J Am Chem Soc 119(48):11691-11692.
13. Chatterji T, et al. (2003) Small molecules that mimic the thiol-triggered alkylating properties seen in the natural product leinamycin. J Am Chem Soc 125(17):4996-4997.
14. Keerthi K, Rajapakse A, Sun D, Gates KS (2013) Synthesis and characterization of a small analogue of the anticancer natural product leinamycin. Bioorg Med Chem 21(1):235-241.
15. Cheng YQ, Tang GL, Shen B (2002) Identification and localization of the gene cluster encoding biosynthesis of the antitumor macrolactam leinamycin in Streptomyces atroolivaceus S-140. J Bacteriol 184(24):7013-7024.
16. Cheng YQ, Tang GL, Shen B (2003) Type I polyketide synthase requiring a discrete acyltransferase for polyketide biosynthesis. Proc Natl Acad Sci USA 100(6):3149-3154.
17. Tang GL, Cheng YQ, Shen B (2004) Leinamycin biosynthesis revealing unprecedented architectural complexity for a hybrid polyketide synthase and nonribosomal peptide synthetase. Chem Biol 11(1):33-45.
18. Tang GL, Cheng YQ, Shen B (2006) Polyketide chain skipping mechanism in the biosynthesis of the hybrid nonribosomal peptide-polyketide antitumor antibiotic leinamycin in Streptomyces atroolivaceus S-140. J Nat Prod 69(3):387-393.
19. Tang GL, Cheng YQ, Shen B (2007) Chain initiation in the leinamycin-producing hybrid nonribosomal peptide/polyketide synthetase from Streptomyces atroolivaceus S-140: Discrete, monofunctional adenylation enzyme and peptidyl carrier protein that directly load D-alanine. J Biol Chem 282(28):20273-20282.
20. Liu T, Huang Y, Shen B (2009) Bifunctional acyltransferase/decarboxylase LnmK as the missing link for beta-alkylation in polyketide biosynthesis. J Am Chem Soc 131(20): 6900-6901.
21. Huang Y, et al. (2011) Characterization of the lnmKLM genes unveiling key intermediates for β-alkylation in leinamycin biosynthesis. Org Lett 13(3):498-501.
22. Lohman JR, Bingman CA, Phillips GN, Jr, Shen B (2013) Structure of the bifunctional acyltransferase/decarboxylase LnmK from the leinamycin biosynthetic pathway revealing novel activity for a double-hot-dog fold. Biochemistry 52(5):902-911.
23. Cerutti PA (1985) Prooxidant states and tumor promotion. Science 227(4685):375-381.
24. Pizzimenti S, Toaldo C, Pettazzoni P, Dianzani MU, Barrera G (2010) The "two-faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer. Cancers (Basel) 2(2):338-363.
25. Kieser T, Bibb MJ, Butter MJ, Chater KF, Hopwood DA (2000) Practical Streptomyces Genetics (John Innes Foundation, Norwich, UK).
26. Ripple MO, Henry WF, Rago RP, Wilding G (1997) Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89(1):40-48.
27. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R (1999) Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 91(14):1227-1232.
28. Kee K, et al. (2004) Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. JBiolChem279(26):27050-27058.
29. Kee K, et al. (2004) Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice. J Biol Chem 279(38):40076-40083.
30. Casero RA, Jr, et al. (2003) The role of polyamine catabolism in anti-tumour drug response. Biochem Soc Trans 31(2):361-365.
31. Basu HS, et al. (2009) A small molecule polyamine oxidase inhibitor blocks androgeninduced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 69(19):7689-7695.
32. Peng X, Gandhi V (2012) ROS-activated anticancer prodrugs: A new strategy for tumor-specific damage. Ther Deliv 3(7):823-833.
33. Major Jourden JL, Cohen SM (2010) Hydrogen peroxide activated matrix metalloproteinase inhibitors: A prodrug approach. Angew Chem Int Ed Engl 49(38):6795-6797.
34. Kuang Y, Balakrishnan K, Gandhi V, Peng X (2011) Hydrogen peroxide inducible DNA crosslinking agents: Targeted anticancer prodrugs. J Am Chem Soc 133(48):19278-19281.
35. Cao S, Wang Y, Peng X (2012) ROS-inducible DNA cross-linking agent as a new anticancer prodrug building block. Chemistry 18(13):3850-3854.
36. Hagen H, et al. (2012) Aminoferrocene-based prodrugs activated by reactive oxygen species. J Med Chem 55(2):924-934.